Our inventor and lead scientist, Professor Richard Mithen, has developed a new broccoli, using traditional breeding techniques, which contains significantly higher amounts of Glucoraphanin compared to standard broccoli varieties.
Professor Richard Mithen
In clinical research on the impact of glucoraphanin-rich broccoli soup on early stage prostate cancer, led by Professor Mithen, volunteers were fed once-weekly a soup incorporating broccoli that had a high levels of glucoraphanin. It was found that the soup reduced elevated levels of fasting blood glucose to levels that are considered more healthy.
Type 2 Diabetes (T2D) is a huge public health issue and is growing in frequency across the developed and developing world. Large swathes of the population are clinically overweight and at risk of developing T2D.
This global population, commonly referred to as pre-diabetic, represents an enormous societal health risk impacting individuals and health services across the world. Whilst T2D is treatable, it is currently not fully reversible and it can lead to serious health problems.
Prediabetes is characterised by the presence of blood glucose levels that are higher than normal but not yet high enough to be classed as diabetes. Prediabetes may be referred to as impaired fasting glucose (IFT), if you have higher than normal sugar levels after a period of fasting, or an impaired glucose tolerance (IGT), if you have higher than normal sugar levels following eating.
The increasing number of new cases of prediabetes presents a global concern as it carries large scale implications towards the future burden on healthcare. Between 2003 and 2011, the prevalence of prediabetes in England alone more than tripled, with 35.3% of the adult population, or 1 in every 3 people having prediabetes.